Assessing the Budget Impact of Bimekizumab in the Management of Hidradenitis Suppurativa in France
Author(s)
Anne Cécile Ezzano, MD1, Ziad Reguiai, MD2, Esther Fabre, PharmD3, Ilona Burgard, PharmD4, Rémi Monnier, MSc4, Michael Frank Mørup, MSc5, Gérard André De Pouvourville, PhD6.
11Hopital d'Instruction des Armées Begin, Saint-Mandé, France, 2Polyclinique Courlancy-Bezannes, Reims, France, 3UCB Pharma SA, Colombes, France, 4PASS, Paris, France, 5UCB Pharma, Copenhagen S, Denmark, 6ESSEC BUSINESS SCHOOL, Paris, France.
11Hopital d'Instruction des Armées Begin, Saint-Mandé, France, 2Polyclinique Courlancy-Bezannes, Reims, France, 3UCB Pharma SA, Colombes, France, 4PASS, Paris, France, 5UCB Pharma, Copenhagen S, Denmark, 6ESSEC BUSINESS SCHOOL, Paris, France.
OBJECTIVES: This study assessed the budget impact of introducing bimekizumab, a humanised monoclonal immunoglobulin (Ig)-G1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, as a treatment option for patients with moderate-to-severe Hidradenitis Suppurativa (HS) in France. HS is a chronic inflammatory skin disease that severely impairs quality of life. It is characterized by recurrent painful nodules, abscesses and draining sinus tracts in primarily intertriginous areas.
METHODS: A Budget Impact (BI) Model with a 5-year time horizon was developed to estimate the economic impact of introducing bimekizumab into the therapeutic strategy from the French payer perspective. The BI analysis included all relevant comparators (Adalimumab including its biosimilars and Secukinumab) in HS. Two scenarios were compared: one with bimekizumab and one without. Direct medical costs included treatment acquisition (list prices), administration, disease management, costs associated with adverse events (AE) and sick leave (assuming 62% employment among French HS patients). Clinical data came from published network meta-analyses (patients’ proportion achieving Hidradenitis Suppurativa Clinical Response HiSCR50 - Naik et al. EADV 2024) and clinical trials (AE incidence). Target populations (2,000 patients) assessed by the French Health Authority (HAS) were considered with an annual growth rate of 0,25 %.
RESULTS: With the introduction of bimekizumab, in the fifth year, total patient care costs reach 33,950,249 € versus 32,238,749 € without it.Between 2025 and 2029, the budgetary impact ranges from 1,092,671 to 1,757,688 million euros per year. In year five, this represents an average marginal increase of about 5% in Health Insurance expenses for this indication.
CONCLUSIONS: In France, bimekizumab is expected to moderately increase the overall budget for patient care over five years, mainly due to drug acquisition costs. Overall, the financial impact remains manageable, supporting the value of bimekizumab in improving patient outcomes while maintaining sustainable spending.
METHODS: A Budget Impact (BI) Model with a 5-year time horizon was developed to estimate the economic impact of introducing bimekizumab into the therapeutic strategy from the French payer perspective. The BI analysis included all relevant comparators (Adalimumab including its biosimilars and Secukinumab) in HS. Two scenarios were compared: one with bimekizumab and one without. Direct medical costs included treatment acquisition (list prices), administration, disease management, costs associated with adverse events (AE) and sick leave (assuming 62% employment among French HS patients). Clinical data came from published network meta-analyses (patients’ proportion achieving Hidradenitis Suppurativa Clinical Response HiSCR50 - Naik et al. EADV 2024) and clinical trials (AE incidence). Target populations (2,000 patients) assessed by the French Health Authority (HAS) were considered with an annual growth rate of 0,25 %.
RESULTS: With the introduction of bimekizumab, in the fifth year, total patient care costs reach 33,950,249 € versus 32,238,749 € without it.Between 2025 and 2029, the budgetary impact ranges from 1,092,671 to 1,757,688 million euros per year. In year five, this represents an average marginal increase of about 5% in Health Insurance expenses for this indication.
CONCLUSIONS: In France, bimekizumab is expected to moderately increase the overall budget for patient care over five years, mainly due to drug acquisition costs. Overall, the financial impact remains manageable, supporting the value of bimekizumab in improving patient outcomes while maintaining sustainable spending.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE58
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Biologics & Biosimilars, Sensory System Disorders (Ear, Eye, Dental, Skin)